Resolution of Refractory Eosinophilic Esophagitis with the Leukocyte-Trafficking Inhibitor Natalizumab
- 9 Downloads
The report by Grandinetti and colleagues showing that vedolizumab may be an effective rescue therapy for eosinophilic gastroenteritis  should stimulate further interest and exploration of the leukocyte-trafficking inhibitors in gastrointestinal inflammatory diseases, including those such as eosinophilic gastroenteritis where the dominant inflammatory cells are not lymphocytes (which are of course the classical target of the α4β7 integrin inhibitors ). Indeed another small series has also reported efficacy of vedolizumab as rescue therapy in some cases of refractory eosinophilic gastroenteritis . Eosinophilic esophagitis (EoE) is part of the spectrum of eosinophilic GI disease, although as Grandinetti et al. describe, the esophagus can be involved in the more classical pan-enteric disease form, but isolated EoE is probably a more specific localized disease with individual etiology and treatment strategies . Neither of those two recent reports examined the effect...
- 1.Grandinetti T, Biedermann L, Bussmann C, Straumann A, Hruz P. Eosinophilic gastroenteritis: clinical manifestation, natural course, and evaluation of treatment with corticosteroids and vedolizumab. Dig Dis Sci. (Epub ahead of print). https://doi.org/10.1007/s10620-019-05617-3.
- 6.Rice GPA, Hartung H-P, Calabresi PA. Anti-α4 integrin therapy for multiple sclerosis. Mech Ration. 2005;64:1336–1342.Google Scholar
- 7.Tramacere I, Del Giovane C, Salanti G, D’Amico R, Filippini G. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev. 2015;9:CD011381.Google Scholar
- 8.MacDonald JK, McDonald JW. Natalizumab for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2007;1:CD006097.Google Scholar